Piramal Pharma to acquire remaining 26% stake in Yapan Bio
With the acquisition, Piramal will fully embed Yapan’s advanced large molecule capabilities into its integrated service offering
Read at The Hindu(opens in a new tab)
Full coverage
Piramal Pharma to acquire remaining 26% stake in Yapan Bio (opens The Hindu in a new tab)
With the acquisition, Piramal will fully embed Yapan’s advanced large molecule capabilities into its integrated service offering

